Attached files
| file | filename |
|---|---|
| 8-K - BIO-PATH HOLDINGS, INC. FORM 8-K - BIO-PATH HOLDINGS INC | fm8k-1109.htm |
Exhibit
99.1
Form
8-K
Bio-Path
Holdings, Inc.
File No.
000-53404
Bio-Path
Holdings, Inc. Operations Update
FOR
IMMEDIATE RELEASE
November 2, 2009 HOUSTON, TX –
Bio-Path Holdings, Inc., (OTC BB: BPTH), a publicly traded biotechnology company
with drug development operations in Houston, Texas, issued a news release today
in which the Company provided an update of drug development
operations.
Previously
in June of 2009, Bio-Path Holdings, Inc. issued a press release in which drug
development operations and the status of commencing a Phase I clinical trial in
the Company’s lead drug candidate were discussed. In that update, the
Company indicated that the next major milestones were successful manufacturing
of the clinical drug batch to be used in the Phase I trial and submission of all
drug manufacturing and testing data to the U.S. Food and Drug Administration
(FDA). The Company confirms today that its suppliers have
successfully manufactured the clinical drug batch and that all release testing
required for this drug has been completed. As a result, Bio-Path
Holdings, Inc. in October submitted the necessary drug batch manufacturing and
testing data to the FDA. Assuming FDA reviewers have no additional
requests for information, the Company expects within thirty (30) days that the
Investigational New Drug (IND) application for its lead drug candidate will be
released. Bio-Path Holdings, Inc. would then be able to commence its
Phase I clinical trial.
About Bio-Path Holdings,
Inc.
Bio-Path
Holdings, Inc. is developing leading edge, patented, liposomal drug delivery
systems developed at The University of Texas M. D. Anderson Cancer Center with
two clinical cancer drug candidates ready for the clinic and a third siRNA
cancer drug undergoing final pre-clinical development. Bio-Path’s
drug delivery technology distributes nucleic acid drugs systemically, throughout
the human body, via simple intravenous infusion. The delivery technology can be
applied both to double stranded (siRNA) and single stranded (antisense) nucleic
acid compounds with the potential to revolutionize the treatment of cancer and
other diseases where drugable targets of disease are well
characterized. Bio-Path Holdings, Inc. will also be developing
liposome tumor targeting technology, representing next-generation enhancements
to the Company’s core liposome delivery technology.
Contact
Information:
Internal
Public Relations:
Douglas
P. Morris, VP Corporate Development
Tel
801.580.2326